Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25381943 | 1.00 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20722208 | 1.00 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL11047147 | 0.95 | MAPT (0.56) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL6534784 | 0.93 | MAPT (0.57) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL9184368 | 0.90 | MAPT (0.55) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL27975925 | 0.89 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL27548463 | 0.89 | MAPT (0.60) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL312835 | 0.89 | MAPT (0.53) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20722209 | 0.87 | MAPT (0.58) | MAPTMAPK1KMT2AALDH1A1LMNA | |
| SCHEMBL20912969 | 0.87 | MAPT (0.58) | MAPTMAPK1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023167944-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-3445743-B1 | PRODRUG OF AMINO ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-10689327-B2 | Prodrug amino acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190337887-A1 | PRODRUG OF AMINO ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
| US-10464884-B2 | Prodrug of amino acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190047943-A1 | PRODRUG OF AMINO ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
| US-10689327-B2 | Prodrug amino acid derivative | GRIN2A, SLC1A2, SLC1A1 | MAPT 158/4885MAPK1 1608/4885KMT2A 439/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
| US-20190337887-A1 | PRODRUG OF AMINO ACID DERIVATIVE | GRIN2A, SLC1A2, SLC1A1 | MAPT 154/4885MAPK1 1559/4885KMT2A 402/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
| US-10464884-B2 | Prodrug of amino acid derivative | GRIN2A, SLC1A2, SLC1A1 | MAPT 154/4885MAPK1 1559/4885KMT2A 402/4885 |
| US-20190047943-A1 | PRODRUG OF AMINO ACID DERIVATIVE | GRIN2A, SLC1A2, SLC1A1 | MAPT 154/4885MAPK1 1559/4885KMT2A 402/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | MAPT 2309/4885MAPK1 4670/4885KMT2A 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.